NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets

21 Dec 2012

• By John Davis

The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.

A new U.K. biotech has been set up by former researchers at GlaxoSmithKline PLC‘s discontinued neurosciences discovery unit and has just raised £11.5 million ($18.4 million) in a Series A financing led by Novo AS and Advent Venture Partners, and including GSK as an investor.

NeRRe Therapeutics has acquired a portfolio of neurokinin antagonists from GSK and has a lead compound it expects to enter...